← back to search

Gema Ruiz‐Hurtado

Royal Institution of Chartered Surveyors · GB
Area of research
Cardiology and Cardiovascular Medicine · Nephrology
Research interest
Research interests include Blood Pressure and Hypertension Studies, Chronic Kidney Disease and Diabetes, Hormonal Regulation and Hypertension, and Cardiac electrophysiology and arrhythmias.
h-index
35
citations
4,342
works
221
NIH funding
primary concept
Medicine
email

Recent publications

Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho.
2026cited by 0position: contributordoi
Recombinant Klotho administration after myocardial infarction reduces ischaemic injury and arrhythmias by blocking intracellular calcium mishandling and CaMKII activation.
2025cited by 9position: contributordoi
Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic (CKM) Syndrome.
2025cited by 3position: contributordoi
Description of Motor Stereotypies in Adolescents and Adults With Autistic Spectrum Disorder
Actas Españolas de Psiquiatría 2025cited by 2position: contributordoi
Atrial Myopathy and Heart Failure: Immunomolecular Mechanisms and Clinical Implications.
2025cited by 1position: contributordoi
Towards a better prevention in cardio-kidney metabolic syndrome: Role of aldosterone and albuminuria.
2025cited by 0position: contributordoi
Is Fibroblast Growth Factor (FGF)23 a Player or a Trigger in Atrial Fibrillation?
2025cited by 0position: contributordoi
Cardiovascular disease in women with early-onset preeclampsia: a matched case-control study.
2025cited by 0position: contributordoi
Artificial Intelligence-Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure.
2025cited by 0position: contributordoi
Albumin Redox Modifications Promote Cell Calcification Reflecting the Impact of Oxidative Status on Aortic Valve Disease and Atherosclerosis.
2024cited by 6position: contributordoi
Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study.
2024cited by 5position: contributordoi
Hypertension and the kidney: an update.
2024cited by 2position: contributordoi
The Urinary Glycopeptide Profile Differentiates Early Cardiorenal Risk in Subjects Not Meeting Criteria for Chronic Kidney Disease.
2024cited by 1position: contributordoi
Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients.
2023cited by 199position: contributordoi
Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation.
2023cited by 138position: contributordoi
Prevention of cardiorenal damage: importance of albuminuria.
2023cited by 59position: contributordoi
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.
2023cited by 54position: contributordoi
Chronic kidney disease promotes atrial fibrillation via inflammasome pathway activation.
2023cited by 54position: contributordoi
Cardiovascular and renal health: Preeclampsia as a risk marker.
2023cited by 5position: contributordoi
Targeting the TWEAK-Fn14 pathway prevents dysfunction in cardiac calcium handling after acute kidney injury.
2023cited by 5position: contributordoi
Global Oxidative Status Is Linked to Calcific Aortic Stenosis: The Differences Due to Diabetes Mellitus and the Effects of Metformin.
2023cited by 4position: contributordoi
Partial Genetic Deletion of Klotho Aggravates Cardiac Calcium Mishandling in Acute Kidney Injury.
2023cited by 4position: contributordoi
Counteracting aldosterone in cardiorenal disease in type 2 diabetes through finerenone administration.
2023cited by 0position: contributordoi
Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
Journal of Hypertension 2022cited by 89position: middledoi
Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease
Kidney International 2022cited by 52position: middledoi
Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.
2022cited by 41position: contributordoi
Klotho relieves inflammation and exerts a cardioprotective effect during renal ischemia/reperfusion-induced cardiorenal syndrome.
2022cited by 39position: contributordoi
Unilateral Acute Renal Ischemia-Reperfusion Injury Induces Cardiac Dysfunction through Intracellular Calcium Mishandling.
2022cited by 14position: contributordoi
Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca<sup>2+</sup> Handling and NRF2 Activation.
2022cited by 12position: contributordoi
Interplay between mineral bone disorder and cardiac damage in acute kidney injury: from Ca<sup>2+</sup> mishandling and preventive role of Klotho in mice to its potential mortality prediction in human.
2022cited by 11position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 19 papers (2020–2026)Julián Segura · Spanish Clinical Research Network13 papers (2019–2025)Juan Antonio López · Spanish National Centre for Cardiovascular Research8 papers (2019–2026)Luis M. Ruilope · Spanish Clinical Research Network7 papers (2019–2025)Jesús Vázquez · Autonomous University of Tamaulipas7 papers (2019–2026)Elena Rodriguez‐Sánchez · Royal Institution of Chartered Surveyors5 papers (2020–2026)Alejandro Lucia · Instituto de Efectividad Clínica y Sanitaria5 papers (2019–2023)Bryan Williams · British Heart Foundation4 papers (2019–2025)Alberto Ortíz · Department of Public Health4 papers (2021–2025)Pedro L. Valenzuela · Universidad de Alcalá4 papers (2020–2023) · 4 papers (2020–2023) · 4 papers (2021–2026)Fernando Arribas · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias3 papers (2019–2022)Ana B. Sanz · Instituto de Salud Carlos III3 papers (2021–2025)Manuel Gorostidi · Universidad de Oviedo3 papers (2019–2025) · 3 papers (2023–2025)Luís M. Ruilope · Harvard University2 papers (2020–2022)Peter Kolkhof · Bayer (United States)2 papers (2020–2022)Marta Gil Fernández · Instituto de Investigaciones Biomédicas Sols-Morreale2 papers (2025–2026)Lisardo Boscá · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias2 papers (2022–2025)